Cite
HARVARD Citation
Papazoglou, A. et al. (2022). Proprotein convertase subtilisin/kexin type 9 inhibitors on the horns of a dilemma: which lipoprotein we should primarily target – low-density lipoprotein or lipoprotein(a)?. Journal of cardiovascular medicine. 23 (9), pp. 635-636. [Online].